Recent Progress in the Treatment of Cancer in Children

被引:72
作者
Butler, Erin [1 ,2 ,3 ]
Ludwig, Kathleen [1 ,2 ,3 ]
Pacenta, Holly L. [4 ]
Klesse, Laura J. [1 ,2 ,3 ]
Watt, Tanya C. [1 ,2 ,3 ]
Laetsch, Theodore W. [5 ,6 ,7 ,8 ]
机构
[1] Univ Texas Southwestern Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA
[2] Univ Texas Southwestern Med Ctr Dallas, Harold C Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA
[3] Childrens Hlth, Dallas, TX USA
[4] Cook Childrens Med Ctr, Div Hematol & Oncol, Ft Worth, TX USA
[5] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA
[6] Childrens Hosp Philadelphia, Ctr Childhood Canc Res, Philadelphia, PA 19104 USA
[7] Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA
[8] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
关键词
cancer of childhood; chemotherapy; clinical trials; pediatrics; ACUTE LYMPHOBLASTIC-LEUKEMIA; LARGE-CELL LYMPHOMA; ACUTE MYELOID-LEUKEMIA; REFRACTORY SOLID TUMORS; NON-HODGKIN-LYMPHOMA; EVENT-FREE SURVIVAL; TERM-FOLLOW-UP; PEDIATRIC-PATIENTS; YOUNG-ADULTS; HIGH-RISK;
D O I
10.3322/caac.21665
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Although significant improvements have been made in the outcomes of children with cancer, the pace of improvement has slowed in recent years as the limits of therapy intensification may have been reached for many pediatric cancers. Furthermore, with increasing numbers of pediatric cancer survivors, the long-term side effects of treatment have become increasingly apparent. Therefore, attention has shifted to the use of molecularly targeted agents and immunotherapies to improve the outcomes of children who are not cured by traditional cytotoxic chemotherapies and to decrease exposure to cytotoxic chemotherapy and reduce late effects. This review describes the recent progress in the treatment of children with cancer, focusing in particular on diseases in which targeted and immunotherapeutic agents have made an impact.
引用
收藏
页码:315 / 332
页数:18
相关论文
共 166 条
[1]   Improving the outcome for children with cancer: Development of targeted new agents [J].
Adamson, Peter C. .
CA-A CANCER JOURNAL FOR CLINICIANS, 2015, 65 (03) :212-220
[2]   Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial [J].
Allen, Carl E. ;
Laetsch, Theodore W. ;
Mody, Rajen ;
Irwin, Meredith S. ;
Lim, Megan S. ;
Adamson, Peter C. ;
Seibel, Nita L. ;
Parsons, D. Williams ;
Cho, Y. Jae ;
Janeway, Katherine .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (05)
[3]   Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma [J].
Armand, Philippe ;
Rodig, Scott ;
Melnichenko, Vladimir ;
Thieblemont, Catherine ;
Bouabdallah, Kamal ;
Tumyan, Gayane ;
Ozcan, Muhit ;
Portino, Sergio ;
Fogliatto, Laura ;
Caballero, Maria D. ;
Walewski, Jan ;
Gulbas, Zafer ;
Ribrag, Vincent ;
Christian, Beth ;
Perini, Guilherme Fleury ;
Salles, Gilles ;
Svoboda, Jakub ;
Zain, Jasmine ;
Patel, Sanjay ;
Chen, Pei-Hsuan ;
Ligon, Azra H. ;
Ouyang, Jing ;
Neuberg, Donna ;
Redd, Robert ;
Chatterjee, Arkendu ;
Balakumaran, Arun ;
Orlowski, Robert ;
Shipp, Margaret ;
Zinzani, Pier Luigi .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (34) :3291-+
[4]   Long-Term Outcomes Among Adult Survivors of Childhood Central Nervous System Malignancies in the Childhood Cancer Survivor Study [J].
Armstrong, Gregory T. ;
Liu, Qi ;
Yasui, Yutaka ;
Huang, Sujuan ;
Ness, Kirsten K. ;
Leisenring, Wendy ;
Hudson, Melissa M. ;
Donaldson, Sarah S. ;
King, Allison A. ;
Stovall, Marilyn ;
Krull, Kevin R. ;
Robison, Leslie L. ;
Packer, Roger J. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (13) :946-958
[5]   Ewing's sarcoma [J].
Balamuth, Naomi J. ;
Womer, Richard B. .
LANCET ONCOLOGY, 2010, 11 (02) :184-192
[6]   Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma [J].
Baldwin, Paige ;
Likhotvorik, Rostislav ;
Baig, Nabeela ;
Cropper, Jodie ;
Carlson, Ruth ;
Kurmasheva, Raushan ;
Sridhar, Srinivas .
FRONTIERS IN ONCOLOGY, 2019, 9
[7]   A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study [J].
Banerjee, Anuradha ;
Jakacki, Regina I. ;
Onar-Thomas, Arzu ;
Wu, Shengjie ;
Nicolaides, Theodore ;
Poussaint, Tina Young ;
Fangusaro, Jason ;
Phillips, Joanna ;
Perry, Arie ;
Turner, David ;
Prados, Michael ;
Packer, Roger J. ;
Qaddoumi, Ibrahim ;
Gururangan, Sridharan ;
Pollack, Ian F. ;
Goldman, Stewart ;
Doyle, Lawrence A. ;
Stewart, Clinton F. ;
Boyett, James M. ;
Kun, Larry E. ;
Fouladi, Maryam .
NEURO-ONCOLOGY, 2017, 19 (08) :1135-1144
[8]   Phase I/II trial assessing bortezomlb and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma [J].
Berenson, JR ;
Yang, HH ;
Sadler, K ;
Jarutirasarn, SG ;
Vescio, RA ;
Mapes, R ;
Purner, M ;
Lee, SP ;
Wilson, J ;
Morrison, B ;
Adams, J ;
Schenkein, D ;
Swift, R .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (06) :937-944
[9]   Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review [J].
Berger, Garrett K. ;
McBride, Ali ;
Lawson, Stephanie ;
Royball, Kelsey ;
Yun, Seongseok ;
Gee, Kevin ;
Bin Riaz, Irbaz ;
Saleh, Ahlam A. ;
Puvvada, Soham ;
Anwer, Faiz .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 109 :42-50
[10]   The combination of bortezomib with chemotherapy to treatrelapsed/refractory acute lymphoblastic leukaemia of childhood [J].
Bertaina, Alice ;
Vinti, Luciana ;
Strocchio, Luisa ;
Gaspari, Stefania ;
Caruso, Roberta ;
Algeri, Mattia ;
Coletti, Valentina ;
Gurnari, Carmelo ;
Romano, Mariateresa ;
Cefalo, Maria Giuseppina ;
Girardi, Katia ;
Trevisan, Valentina ;
Bertaina, Valentina ;
Merli, Pietro ;
Locatelli, Franco .
BRITISH JOURNAL OF HAEMATOLOGY, 2017, 176 (04) :629-636